IMR Press / EJGO / Volume 29 / Issue 1 / pii/1630995328739-804304725

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research
L1 (CAM) (CD171) in ovarian serous neoplasms
Show Less
1 Department of Obstetrics & Gynecology, University Hospital of Larissa, Larissa
2 Department of Pathology, University Hospital of Larissa, Larissa
3 Laboratory of Cytogenetics and Molecular Genetics, University Hospital of Larissa, Larissa
4 Department of Hygiene and Epidemiology, University Hospital of Larissa, Larissa (Greece)
Eur. J. Gynaecol. Oncol. 2008, 29(1), 26–30;
Published: 10 February 2008

Purpose of the investigation: The evaluation of L1 (CAM) as a tumor progression marker and as a prognostic factor in serous ovarian tumors. Methods: L1 (CAM) protein expression was assessed by immunohistochemistry and Western blot in serous ovarian tumors [cystadenomas (n = 20), borderline tumors (n = 14) and carcinomas (n = 47)], and was correlated with stage,grade, progression- free survival time (PFS) and overall survival. Results: L1 (CAM) immunoreactivity correlated significantly with stage and grade. It increased from benign tumors to early carcinomas and to advanced stage carcinomas progressively and significantly. In Stage III G3 carcinoma patients, low L1 (CAM) expressing tumors exhibited better response to chemotherapy and were associated with statistically significantly longer PFS (p = 0.002). Conclusion: L1 (CAM) expression represents a novel diagnostic marker in serous ovarian neoplasms that shows characteristics of tumor progression. L1 expression was associated with chemotherapy response.
L1 (CAM)
Ovarian cancer
Prognostic factor
Tumor progression
Back to top